MP-101

About Mitochon Pharmaceuticals

Mitochon Pharmaceuticals is a private, clinical-stage biotech leveraging a platform of mitochondrial-targeting chemical uncouplers/ionophores to address a range of neurodegenerative diseases with high unmet need. The company's lead programs, MP-101 and MP-201, are backed by preclinical data demonstrating neuroprotection in models of ALS, Huntington's, Parkinson's, Alzheimer's, Multiple Sclerosis, and Traumatic Brain Injury. Led by a seasoned team with prior exit and NDA approval experience, Mitochon is pursuing a novel, upstream approach to disease modification but faces the inherent risks of early clinical development and platform validation.

About Novaremed

Novaremed is a Swiss biotech innovating in non-opioid pain management, targeting the high-unmet need in neuropathic pain conditions. Its lead asset, nispomeben, is a novel small molecule with a distinct mechanism of action, currently in an NIH-funded Phase 2b trial for diabetic neuropathy. The company is privately held, pre-revenue, and leverages strategic partnerships and grant funding to advance its clinical programs, positioning itself as a potential disruptor in the pain therapeutics market.

About Medesis Pharma

Medesis Pharma is a private, clinical-stage biotech leveraging its proprietary Aonys® technology platform, which utilizes reverse micelle nano-carriers derived from sugar-based surfactants for non-invasive drug delivery, particularly to the brain. The company's lead program, ALA-2000 (cerebral adrenoleukodystrophy), is in Phase 1/2, targeting a severe rare neurological disease with no approved non-invasive therapy. With a focus on CNS and rare diseases, Medesis aims to address significant unmet medical needs by reformulating existing drugs to enhance their therapeutic potential and safety profiles. The company operates as a platform-focused therapeutics developer and is currently in a pre-revenue stage.

Therapeutic Areas

Other Multiple Indications (Neurodegenerative) Drugs